When was the last time you measured your waistline? If you assume that BMI is the only number to focus on when it comes to your health, think twice. New research has revealed a shocking revelation—your waist circumference might be a far better predictor of men's cancer risk than BMI.

The study finds that for each 4-inch increase in waist size, a man's risk of cancer increases by a staggering 25%. Meanwhile, BMI, commonly regarded as the gold standard for assessing obesity, raises cancer risk by only 19% for the same weight gain. So, if you've been dismissing that pesky belly fat, it's time to take notice.

But why is your waistline so important? The reason is visceral fat—the hidden, deep fat that accumulates around your organs. Unlike other body fat, visceral fat is a stealthy troublemaker, causing inflammation, insulin resistance, and abnormal blood fat levels—all of which combine to create a cancer-perfect storm.

Obesity has been associated with an increased risk of numerous health conditions, including cancer, for decades. The research, though, indicates that a specific measure of the body—waist circumference—may be an even more reliable forecaster of cancer risk in men than the more frequently employed Body Mass Index (BMI). This finding emphasizes the need to pay particular attention to the distribution of fat and not merely to the weight of the body.

BMI has been the go-to measure for years for gauging health risks related to obesity. New research, though, that appears in The Journal of the National Cancer Institute indicates that waist measurement is a better predictor of cancer risk in men. According to the research, four more inches (10 cm) around the waist will add 25% to a man's cancer risk. Conversely, a 3.7 kg/m² rise in BMI (from a BMI of 24 to 27.7) increased cancer risk by only 19%.

Why is waist circumference a better predictor, then? Unlike BMI, which measures weight relative to height, waist circumference actually measures abdominal fat—specifically, visceral fat. This type of fat encircles internal organs and is also linked to higher levels of inflammation, insulin resistance, and abnormal blood lipids, all of which are factors in cancer growth. BMI, however, does not measure fat distribution, so two individuals with the same BMI can have very different levels of health risk depending on where fat is deposited on their bodies.

Why Men Are at Higher Risk?

Interestingly, the research identified a significant difference between men and women when it came to waist circumference and cancer risk. Although waist circumference and BMI were linked with obesity-related cancers in women, the relationship was weaker than for men. An increase of 12 cm (4.7 inches) in waist size or a 4.3 rise in BMI (from 24 to 28.3) raised the cancer risk in women by just 13%—a much lower percentage than for men.

Experts credit this difference to the way that fat is stored in the body. Men are more likely to carry fat around the abdomen, especially as visceral fat, which is more metabolically active and associated with cancer-producing biological alterations. Women, by contrast, store fat in peripheral sites such as the hips and thighs, where it is less likely to drive systemic inflammation and metabolic disturbances.

A possible reason is that men tend to depot fat more in the visceral regions, whereas women tend to carry more subcutaneous and peripheral fat," wrote the researchers. "This may render waist circumference a more robust risk factor for cancer in men and account for why waist circumference provides additional risk information beyond BMI in men but not women."

Cancer Types Most Linked to Abdominal Fat

The research used the International Agency for Research on Cancer (IARC) data to define obesity-related cancers. These cancers are esophageal (adenocarcinoma), gastric (cardia), colorectal, rectal, liver, gallbladder, pancreatic, renal, and thyroid cancers, and multiple myeloma and meningioma. In men, abdominal obesity is especially significant in raising the risk of these cancers through high levels of insulin and markers of inflammation.

For women, the research proposes that both waist circumference and hip circumference may give a more accurate estimate of visceral fat and cancer risk. "Adding hip circumference to risk models could strengthen the link between waist circumference and cancer, especially in women," researchers observed.

What This Means for Men's Health and Cancer Prevention?

With these results, doctors advise men to be more mindful of their waistline than only their BMI. Waist size is an easy method to gauge health risk, and its maintenance through lifestyle changes might be the key to cancer prevention.

How To Reduce Cancer Risk In Men?

Track Your Waist Size: Regularly measure your waist circumference and try to keep it in a healthy range (below 40 inches for men, according to medical advice).

Eat a Balanced Diet: A diet containing high fiber, lean protein, and healthy fats can assist in limiting visceral fat gain.

Exercise Consistently: Regular exercise with a combination of aerobic and strength training will help maintain a healthy waistline.

Control Stress and Sleep: Persistent stress and inadequate sleep tend to cause weight gain, especially in the midsection of the body.

Regular Health Screenings: Early identification of cancer risk factors through regular screening can greatly enhance long-term health status.

While doctors across the world recommend ensuring that fluoride and other protective minerals make up your toothpaste, your body produces its very own amino acid that protect your entire dental cavity.

Arginine, an amino acid that is already present in saliva, can turn bacteria from damaging to protective in your mouth, a study has found.

When sugars from food are broken down by the many bacteria living in the mouth, acids are produced that gradually damage tooth enamel and lead to cavities. This is known as dental caries. Over time, this acid dissolves tooth enamel and causes cavities.

However, researchers at Aarhus University in Denmark have discovered that regular arginine treatment can significantly reduced the overall acidity levels in the mouth and prevent tooth decay.

Yumi Del Rey, microbiologist at Aarhus, said: ""Our results revealed differences in acidity of the biofilms, with the ones treated with arginine being significantly more protected against acidification caused by sugar metabolism."

How Did The Study Take Place?

Volunteers were then asked to instructed to dip the dentures in a sugar solution for 5 minutes, immediately followed by distilled water (as placebo) or arginine for 30 minutes, one on each side. This was to be repeated three times a day, with arginine treatment done on the same side each time.

Sebastian Schlafer, professor at the Department of Dentistry and Oral Health, explained: "The aim was to investigate the impact of arginine treatment on the acidity, type of bacteria, and the carbohydrate matrix of biofilms from patients with active caries."

After 4 days of this process, the biofilms were developed and the dentures were removed for detailed analysis. The researchers compared dental plaques grown on customized dentures on both sides of each participant's mouth using a special pH-sensitive dye called C-SNARF-4.

How Does Arginine Work?

Additionally, the team also began to look into how arginine might be reducing acidity, by taking stock of which bacteria and sugars were present in each sample.

Biofilms treated with arginine showed lower levels of a sugar called fucose, while another sugar, galactose, was concentrated towards the outer surface of the biofilm, meaning both sugars were away from the tooth enamel.

After analyzing the DNA of bacteria present, the researchers found that arginine treatment significantly reduced a specific population of Streptococcus bacteria known to produce acid, while slightly increasing other bacterial strains that can metabolize arginine.

The scientists noted that while more research is needed into the arginine's effectiveness, the amino acid could be a promising new addition to oral hygiene products such as toothpaste or mouthwash.

For decades, a cancer diagnosis often came with fear and uncertainty. Today, that narrative is slowly changing. New national data shows that more people diagnosed with cancer in the United States are living longer than ever before, reflecting steady progress in prevention, early detection, and treatment.

For the first time, the five-year survival rate across all cancers has reached 70 percent. That means seven out of ten people diagnosed with cancer now live at least five years after diagnosis, a significant improvement from the mid-1970s, when survival hovered around 50 percent. This shift marks one of the most encouraging milestones in modern cancer care.

Why Survival Rates Are Rising

Several factors are driving this improvement. Reduced tobacco use has played a major role, particularly in lowering deaths from lung and other smoking-related cancers. At the same time, better screening tools are catching cancers earlier, when treatment is more likely to work. Advances in therapies, including targeted drugs, immunotherapy, and improved chemotherapy regimens, have also transformed outcomes for many patients.

What stands out is that survival gains are not limited to less aggressive cancers. Even cancers once considered highly fatal, such as lung cancer, liver cancer, and certain blood cancers, are seeing meaningful improvements. In some advanced-stage cancers where survival was previously measured in months, people are now living years longer than expected.

Living Longer, Even With Advanced Cancer

One of the most striking trends is improved survival among people with metastatic cancer, where the disease has spread to other parts of the body. While these cancers remain difficult to treat, progress is undeniable. Survival rates for metastatic lung cancer, for example, have increased severalfold since the 1990s. Similar gains have been seen in metastatic colorectal cancers.

These improvements suggest that cancer is increasingly being managed as a long-term condition rather than an immediate terminal illness for many patients. Continued research has played a critical role in making this possible.

The Role of Research and Funding

The steady rise in survival has not happened by chance. It reflects decades of scientific investment, clinical trials, and innovation. However, experts warn that recent cuts to health research funding could slow future progress. Breakthroughs in cancer care rely heavily on sustained support for research, and disruptions to that pipeline could affect outcomes years down the line.

While the current numbers are encouraging, they also serve as a reminder that progress must be protected and expanded.

Persistent Gaps and Disparities

Despite overall gains, cancer outcomes are not improving equally for everyone. The report highlights ongoing racial and ethnic disparities in both cancer incidence and survival. Certain populations continue to experience higher death rates and lower survival, often due to limited access to early screening, timely diagnosis, and high-quality treatment.

Lung cancer is expected to remain the leading cause of cancer-related deaths in the coming years. While smoking remains the biggest risk factor, an increasing number of people who have never smoked are also being diagnosed, raising new questions about environmental and genetic risks. Some experts argue that screening guidelines need to evolve to reflect these changes.

A Growing Community of Survivors

As survival improves, the number of people living with a history of cancer is rapidly growing. There are already over 18 million cancer survivors in the US, and that number is expected to cross 22 million within the next decade. This brings new challenges.

Survivors often face long-term physical, emotional, and financial effects, and the healthcare system is still catching up when it comes to consistent survivorship care. Many primary care providers are not trained to monitor cancer recurrence or manage late treatment effects, leaving gaps in follow-up care.

Covid is returning, as the National Health Service, NHS UK warned that there has been a "bounce back" in respiratory viruses this winter, along with COVID too on the rise. While UK was already struggling with flu and norovirus on the rise, cases of COVID have also risen. The latest data from the UK Health and Security Agency (UKHSA) show that the number of patients in hospital beds with COVID per day has risen from 0.87 per 100,000, as compared with 0.77 per 100,000 the previous week.

NHS national medical director Professor Meghana Pandit said: “It’s clear that the worst is far from over for the NHS this winter, with hospitals again experiencing a rise in patients admitted with flu and other respiratory virus cases last week.”

What New COVID Variants Are We Dealing With In 2026?

Since the pandemic, there have been many variants of COVID. The virus has continued to evolve. Two new variants that caused the spike in cases in autumn were XFG, known as Stratus, and NB.1.1, known as Nimbus.

Stratus: It is a subvariant of Omicron variant and made of previous variants LF.7 and LP.8.1.2. It was first detected in a sample on January 27, 2025. Whereas, Nimbus was first detected on January 22, 2025. It also originated from the same omicron variant, which was the reason for spike in 2023.

The World Health Organization (WHO) describes stratus as a "variant under monitoring" after several countries in South East Asia reported a rise in new cases and hospitalizations with this variant being detected.

COVID Symptoms 2026: Fatigue Emerges As The Most Common Symptom

Among studies that focused on how symptoms appear together, fatigue stood out as the most consistently reported issue. It often occurred alone or alongside problems such as muscle and joint pain, brain fog, or breathlessness. Other symptom pairings that appeared frequently included loss of smell and taste, anxiety with depression, and various forms of musculoskeletal pain.

When researchers classified patients based on affected organ systems, respiratory problems were the most widespread, seen in about 47% of long COVID patients. Neurological symptoms followed at 31%, while gastrointestinal issues were reported by 28%. The authors stressed that these percentages reflect how often these clusters appeared within long COVID cases studied, not how common they are in the general population.

A smaller number of studies sorted patients by how severe their symptoms were, dividing them into mild, moderate, or severe categories using symptom scores, symptom counts, or quality-of-life measures. Three studies used clinical indicators for classification, including abnormal triglyceride levels and signs of restricted lung function on imaging.

As per the Centers for Disease Control and Prevention (CDC), here are the common COVID symptoms:

• Fever or chills
• Cough
• Shortness of breath or difficulty breathing
• Sore throat
• Congestion or runny nose
• New loss of taste or smell
• Fatigue
• Muscle or body aches
• Headache
• Nausea or vomiting
• Diarrhea

How To Know If You Have COVID?

CDC says, look out for these signs:

• Trouble breathing
• Persistent pain or pressure in the chest
• New confusion
• Inability to wake or stay awake
• Lips and nail beds may appear pale, grey or blue